| Literature DB >> 18524998 |
J Andrew Williams1, Tommy Andersson, Tommy B Andersson, Rebecca Blanchard, Martin Otto Behm, Nadine Cohen, Timi Edeki, Monique Franc, Kathleen M Hillgren, Keith J Johnson, David A Katz, Mark N Milton, Bernard P Murray, Joseph W Polli, Deb Ricci, Lisa A Shipley, Subrahmanyam Vangala, Steven A Wrighton.
Abstract
Pharmacogenomic (PGx) research on the absorption, distribution, metabolism, and excretion (ADME) properties of drugs has begun to have impact for both drug development and utilization. To provide a cross-industry perspective on the utility of ADME PGx, the Pharmaceutical Research and Manufacturers of America (PhRMA) conducted a survey of major pharmaceutical companies on their PGx practices and applications during 2003-2005. This white paper summarizes and interprets the results of the survey, highlights the contributions and applications of PGx by industrial scientists as reflected by original research publications, and discusses changes in drug labels that improve drug utilization by inclusion of PGx information. In addition, the paper includes a brief review on the clinically relevant genetic variants of drug-metabolizing enzymes and transporters most relevant to the pharmaceutical industry.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18524998 DOI： 10.1177/0091270008319329
Source DB: PubMed Journal: J Clin Pharmacol ISSN： 0091-2700 Impact factor: 3.126